← Back to Search

GVAX pancreas vaccine for Pancreatic Cancer

Phase 2
Waitlist Available
Led By Daniel A. Laheru, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 years
Awards & highlights

Study Summary

This trial is testing a new vaccine for pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity
Secondary outcome measures
Disease-free Survival (DFS)
Overall Survival (OS)

Side effects data

From 2022 Phase 2 trial • 56 Patients • NCT00389610
100%
Erythema (vaccination site)
100%
Induration (vaccination site)
100%
Pruritus (vaccination site)
91%
Warmth (vaccination site)
82%
Tenderness (vaccination site)
82%
Flu-Like symptoms
36%
Pruritus
36%
Urticaria
36%
Myalgia
36%
Vaccine Flares (vaccination site)
36%
Chills
27%
Blisters
18%
Fatigue
18%
Anorexia
9%
Diarrhea
9%
Skin hyperpigmentation (vaccination site)
9%
Presyncope
9%
Arthralgia
9%
Weakness
9%
Nasal congestion
9%
Dry skin
9%
Lymphadenopathy
9%
Headache
9%
Fever
9%
Bruising (vaccination site)
9%
White blood cell count elevated
9%
Eosinophil count elevated
9%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Previously Vaccinated With GVAX Pancreas Vaccine
GVAX Pancreas Vaccine Naive

Trial Design

2Treatment groups
Experimental Treatment
Group I: Previously Vaccinated With GVAX Pancreas VaccineExperimental Treatment1 Intervention
Participants receive booster vaccination every 6 months, given intradermally.
Group II: GVAX Pancreas Vaccine NaiveExperimental Treatment1 Intervention
Participants will receive GVAX pancreas priming vaccinations once every month for a total of 3 months and every 6 months after that, given intradermally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GVAX pancreas vaccine
2006
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
561 Previous Clinical Trials
33,043 Total Patients Enrolled
The Skip Viragh FoundationOTHER
3 Previous Clinical Trials
113 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,307 Total Patients Enrolled
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top